Recombinant anti-CCR2 antibodies and methods of use therefor

• US 6,727,349 B1
• Filed: 02/03/2000
• Issued: 04/27/2004
• Est. Priority Date: 07/23/1998
• Status: Expired due to Term

• Current Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Original Assignee: Millennium Pharmaceuticals Incorporated (Takeda Pharmaceutical Company Limited)
• Inventors: OʼBrien, Siobhan H., Horvath, Christopher, LaRosa, Gregory J., Newman, Walter, Jones, S. Tarran, OʼKeefe, Theresa
• Primary Examiner(s): HELMS, LARRY RONALD
• Application Number:
  US09/497,625
• Time in Patent Office: 1,545 Days
• Field of Search: 530/387.1, 530/387.3, 530/388.1, 530/388.23, 530/300, 530/350, 424/130.1, 424/133.1, 424/135.1, 424/156.1
• US Class Current: 530/387.3
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/7158 for chemokines
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/24 containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of a cell bearing mammalian CCR2 with a ligand thereof, and to use of the antibodies and fragments in therapeutic, prophylactic and diagnostic methods.

Claims

1. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9 and a light chain framework region derived from the light chain of the HF-21/28 antibody.

2. The humanized immunoglobulin of claim 1 further comprising a constant region derived from a human constant region.

3. The humanized immunuoglobulin of claim 2 wherein the human constant region is of the gamma type.

4. The humanized immunoglobulin of claim 1 wherein the antigen binding region comprises the three complementarity determining regions of the light chain variable region of monoclonal antibody 1D9 and the three complementarity determining regions of the heavy chain variable region of monoclonal antibody 1D9.

5. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from a heavy chain of human origin.

6. The humanized immunoglobulin of claim 5 wherein said immunoglobulin can compete with murine monoclonal antibody 1D9 for binding to CCR2.

7. The humanized immunoglobulin of claim 5 wherein the heavy chain of human origin is the heavy chain of the human 4B4′

CL antibody.

8. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and a suitable carrier.

9. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from a heavy chain of human origin, and a suitable carrier.

10. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9 and a heavy chain framework region derived from the heavy chain of the 4B4′

CL antibody.

11. The humanized immunoglobulin of claim 10 further comprising a constant region derived from a human constant region.

12. The humanized immunoglobulin of claim 11 wherein the human constant region is of the gamma type.

13. The humanized immunoglobulin of claim 10 wherein the antigen binding region comprises the three complementarity determining regions of the light chain variable region of monoclonal antibody 1D9 and the three complementarity determining regions of the heavy chain variable region of monoclonal antibody 1D9.

14. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from a light chain of human origin, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody.

15. The humanized immunoglobulin of claim 14 wherein said immunoglobulin can compete with murine monoclonal antibody 1D9 for binding to CCR2.

16. The humanized immunoglobulin of claim 14 wherein the light chain of human origin is the light chain of the human HF-21/28 antibody.

17. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody, and a suitable carrier.

18. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from a light chain of human origin, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody, and a suitable carrier.

19. A humanized immunoglobulin light chain comprising CDR1, CDR2 and CDR3 of the light chain of monoclonal antibody 1D9 and a light chain framework region derived from a human light chain.

20. The humanized immunoglobulin light chain of claim 19 wherein the human light chain is the light chain of the HF-21/28 antibody.

21. The humanized immunoglobulin light chain of claim 19 comprising the variable region of SEQ ID NO:

9.

22. A humanized immunoglobulin heavy chain comprising CDR1, CDR2 and CDR3 of the heavy chain of monoclonal antibody 1D9 and a heavy chain framework region derived from a human heavy chain.

23. The humanized immunoglobulin heavy chain of claim 22 wherein the human heavy chain is the heavy chain of the human 4B4′

CL antibody.

24. The humanized immunoglobulin heavy chain of claim 22 comprising the variable region of SEQ ID NO:

10.

25. A humanized immunoglobulin light chain comprising an amino acid sequence selected from the group consisting of:

a) SEQ ID NO;

12;

b) SEQ ID NO;

13;

c) SEQ ID NO;

14; and

d) SEQ ID NO;

15.

26. A humanized immunoglobulin heavy chain comprising an amino acid sequence selected from the group consisting of:

a) SEQ ID NO;

17;

b) SEQ ID NO;

18;

c) SEQ ID NO;

19; and

d) SEQ ID NO;

20.

27. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises a variable region selected from the group consisting of SEQ ID NO:

12, SEQ ID NO;

13, SEQ ID NO;

14 and SEQ ID NO;

15, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from a heavy chain of human origin.

28. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9, and wherein said heavy chain comprises a variable region selected from the group consisting of SEQ ID NO:

17, SEQ ID NO;

18, SEQ ID NO;

19 and SEQ ID NO;

20.

29. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin or fragment comprising a heavy chain and a light chain, wherein said light chain comprises a variable region selected from the group consisting of SEQ ID NO:

12, SEQ ID NO;

13, SEQ ID NO;

14 and SEQ ID NO;

15, and wherein said heavy chain comprises a variable region selected from the group consisting of SEQ ID NO;

17, SEQ ID NO;

18, SEQ ID NO;

19 and SEQ ID NO;

20.

30. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising CDR1, CDR2 and CDR3 of the light chain of monoclonal 1D9 antibody and a framework region derived from a human light chain framework region, and a suitable carrier.

31. A pharmaceutical composition according to claim 30 wherein the human light chain framework region is the light chain framework region of the HF-21/28 antibody.

32. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising CDR1, CDR2 and CDR3 of the heavy chain of monoclonal 1D9 antibody and a framework region derived from a human heavy chain framework region, and a suitable carrier.

33. A pharmaceutical composition according to 32 wherein the human heavy chain framework region is the heavy chain framework region of the 4B4′

CL antibody.

34. A humanized immunoglobulin light chain comprising the amino acid sequence of SEQ ID NO:

12.

35. A humanized immunoglobulin heavy chain comprising the amino acid sequence of SEQ ID NO:

17.

36. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising a light chain comprising the amino acid sequence of SEQ ID NO:

12 and a heavy chain comprising the amino acid sequence of SEQ ID NO;

17.

37. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising a light chain comprising the amino acid sequence of SEQ ID NO:

12 and a heavy chain comprising the amino acid sequence of SEQ ID NO;

17, and a suitable carrier.

38. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9, a light chain framework region derived from the light chain of the HF-21/28 antibody, and a heavy chain framework region derived from the heavy chain of the 4B4′

CL antibody.

39. A humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody.

40. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9, a light chain framework region derived from the light chain of the HF-21/28 antibody, and a heavy chain framework region derived from the heavy chain of the 4B4′

CL antibody, and a suitable carrier.

41. A pharmaceutical composition comprising a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2) comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody, and a suitable carrier.

42. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9 and a light chain framework region derived from the light chain of the HF-21/28 antibody.

43. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from a heavy chain of human origin.

44. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and a suitable carrier.

45. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from a heavy chain of human origin, and a suitable carrier.

46. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9 and a heavy chain framework region derived from the heavy chain of the 4B4′

CL antibody.

47. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from a light chain of human origin, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody.

48. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody, and a suitable carrier.

49. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from a light chain of human origin, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody, and a suitable carrier.

50. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises a variable region selected from the group consisting of SEQ ID NO:

12, SEQ ID NO;

13, SEQ ID NO;

14 and SEQ ID NO;

15, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from a heavy chain of human origin.

51. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9, and wherein said heavy chain comprises a variable region selected from the group consisting of SEQ ID NO:

17, SEQ ID NO;

18, SEQ ID NO;

19 and SEQ ID NO;

20.

52. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises a variable region selected from the group consisting of SEQ ID NO:

12, SEQ ID NO;

13, SEQ ID NO;

14 and SEQ ID NO;

15, and wherein said heavy chain comprises a variable region selected from the group consisting of SEQ ID NO;

17, SEQ ID NO;

18, SEQ ID NO;

19 and SEQ ID NO;

20.

53. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising CDR1, CDR2 and CDR3 of the light chain of monoclonal 1D9 antibody and a framework region derived from a human light chain framework region, and a suitable carrier.

54. A pharmaceutical composition according to claim 53 wherein the human light chain framework region is the light chain framework region of the HF-21/28 antibody.

55. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising CDR1, CDR2 and CDR3 of the heavy chain of monoclonal 1D9 antibody and a framework region derived from a human heavy chain framework region, and a suitable carrier.

56. A pharmaceutical composition according to claim 55 wherein the human heavy chain framework region is the heavy chain framework region of the 4B4′

CL antibody.

57. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a light chain comprising the amino acid sequence of SEQ ID NO:

12 and a heavy chain comprising the amino acid sequence of SEQ ID NO;

17.

58. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a light chain comprising the amino acid sequence of SEQ ID NO:

12 and a heavy chain comprising the amino acid sequence of SEQ ID NO;

17, and a suitable carrier.

59. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9, a light chain framework region derived from the light chain of the HF-21/28 antibody, and a heavy chain framework region derived from the heavy chain of the 4B4′

CL antibody.

60. An antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody.

61. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising an antigen binding region from monoclonal antibody 1D9, a light chain framework region derived from the light chain of the HF-21/28 antibody, and a heavy chain framework region derived from the heavy chain of the 4B4′

CL antibody, and a suitable carrier.

62. A pharmaceutical composition comprising an antigen binding fragment of a humanized immunoglobulin having binding specificity for CC-chemokine receptor 2 (CCR2), said immunoglobulin comprising a heavy chain and a light chain, wherein said light chain comprises three complementarity determining regions from the light chain of monoclonal antibody 1D9 and a framework region derived from the light chain of the HF-21/28 antibody, and wherein said heavy chain comprises three complementarity determining regions from the heavy chain of monoclonal antibody 1D9 and a framework region derived from the heavy chain of the 4B4′

CL antibody, and a suitable carrier.